SG11201803975SA - Improved tnf binders - Google Patents
Improved tnf bindersInfo
- Publication number
- SG11201803975SA SG11201803975SA SG11201803975SA SG11201803975SA SG11201803975SA SG 11201803975S A SG11201803975S A SG 11201803975SA SG 11201803975S A SG11201803975S A SG 11201803975SA SG 11201803975S A SG11201803975S A SG 11201803975SA SG 11201803975S A SG11201803975S A SG 11201803975SA
- Authority
- SG
- Singapore
- Prior art keywords
- seq
- international
- tnf
- pct
- alpha
- Prior art date
Links
- 239000011230 binding agent Substances 0.000 title abstract 3
- 108060008682 Tumor Necrosis Factor Proteins 0.000 abstract 3
- 102100040247 Tumor necrosis factor Human genes 0.000 abstract 3
- 102000000852 Tumor Necrosis Factor-alpha Human genes 0.000 abstract 2
- 239000003795 chemical substances by application Substances 0.000 abstract 2
- 150000001875 compounds Chemical class 0.000 abstract 2
- 229920001184 polypeptide Polymers 0.000 abstract 2
- 102000004196 processed proteins & peptides Human genes 0.000 abstract 2
- 108090000765 processed proteins & peptides Proteins 0.000 abstract 2
- MZOFCQQQCNRIBI-VMXHOPILSA-N (3s)-4-[[(2s)-1-[[(2s)-1-[[(1s)-1-carboxy-2-hydroxyethyl]amino]-4-methyl-1-oxopentan-2-yl]amino]-5-(diaminomethylideneamino)-1-oxopentan-2-yl]amino]-3-[[2-[[(2s)-2,6-diaminohexanoyl]amino]acetyl]amino]-4-oxobutanoic acid Chemical compound OC[C@@H](C(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CC(O)=O)NC(=O)CNC(=O)[C@@H](N)CCCCN MZOFCQQQCNRIBI-VMXHOPILSA-N 0.000 abstract 1
- 108060003951 Immunoglobulin Proteins 0.000 abstract 1
- 125000003275 alpha amino acid group Chemical group 0.000 abstract 1
- 150000005829 chemical entities Chemical class 0.000 abstract 1
- 102000018358 immunoglobulin Human genes 0.000 abstract 1
- 230000008520 organization Effects 0.000 abstract 1
- 102000004169 proteins and genes Human genes 0.000 abstract 1
- 108090000623 proteins and genes Proteins 0.000 abstract 1
- 102000003390 tumor necrosis factor Human genes 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
- C07K16/241—Tumor Necrosis Factors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/10—Immunoglobulins specific features characterized by their source of isolation or production
- C07K2317/14—Specific host cells or culture conditions, e.g. components, pH or temperature
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/22—Immunoglobulins specific features characterized by taxonomic origin from camelids, e.g. camel, llama or dromedary
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/567—Framework region [FR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/569—Single domain, e.g. dAb, sdAb, VHH, VNAR or nanobody®
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Dermatology (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicinal Preparation (AREA)
- Organic Insulating Materials (AREA)
- Transition And Organic Metals Composition Catalysts For Addition Polymerization (AREA)
- Treatment Of Liquids With Adsorbents In General (AREA)
Abstract
INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property Organization International Bureau (43) International Publication Date .... .crs..1 18 May 2017 (18.05.2017) WIPO I PCT (10) WO International Publication Number 111111111111311111111111111111111111111111111111111111111111111111111311111111111111111 2017/081320 Al (51) International Patent Classification: (81) Designated States (unless otherwise indicated, for every C07K 16/18 (2006.01) C07K 16/24 (2006.01) kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, (21) International Application Number: BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, PCT/EP2016/077595 DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, (22) International Filing Date: HN, HR, HU, ID, IL, IN, IR, IS, JP, KE, KG, KN, KP, KR, 14 November 2016 (14.11.2016) KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, (25) Filing Language: English OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, (26) Publication Language: English SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, (30) Priority Data: ZW. 62/254,375 12 November 2015 (12.11.2015) US (84) Designated States (unless otherwise indicated, for every (71) Applicant: ABLYNX NV [BE/BE]; Technologiepark 21, kind of regional protection available): ARIPO (BW, GH, 9052 Ghent-Zwijnaarde (BE). GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, (72) Inventors: BUYSE, Marie-Ange; Burgemeester Edmond TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, Ronsestraat 23, 9820 Merelbeke (13E). BOUCNEAU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, Joachim; Elsbos 41, 9840 De Pinte (BE). CASTEELS, DK, EE, ES, FL FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, Peter; Lindekouter 20, 9420 Erpe-Mere (BE). VAN LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, HEEKE, Gino; Omloop 35 #203, 9700 Eine (BE). SM, TR), OAPI (BF, BJ, CF, CG, CL CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG). (74) Agents: STEFFERL, Andreas et al.; HOFFMANN Published: EITLE Patent- and Rechtsanwalte PartmbB, ArabellastraBe 30, 81925 Munich (DE). — with international search report (Art 21(3)) [Continued on next page] Title: IMPROVED TNF BINDERS (54) Figure 2 10 20 30 40 SEQ ID NO: 58 QVQLVESGGGLVQAGGSLRLSCTASGQTSSTADMGWFRQP - 5 , - q , SEQ ID NO: 1 E P A SEQ ID NO: 59 E V P F F . A 50 60 70 80 SEQ ID NO: 58 PGKGREFVARISGIDGTTYYDEPVKGRFTTSRDKAQNTVYL SEQ ID NO: 1 S N.K..1... SEQ ID NO: 59 S N.K..L.. I'l .4t 90 100 110 -- abc -- : ---- 1 ---- ---- : labcd ---- ---- : 1 ---- o ei SEQ ID NO: 58 QMDSLKPEDTAVYYCRSPRYADQMSAYDYWGQGTQVTVSS - en SEQ ID NO: 1 N.. L L Il SEQ ID NO: 59 N. k L L Ge C —..„ It-- 1-1 (57) : The present invention relates to amino acid sequences, compounds and polypeptides binding to tumor necrosis factor N alpha (\"TNF\" or \"TNF-alpha\"). In particular, the present invention relates to improved heavy-chain immunoglobulin single variable domains (also referred to herein as \"ISV's\" or \"ISVDs\") binding to tumor necrosis factor alpha, as well as to proteins, polypeptides C and other constructs, compounds, molecules or chemical entities that comprise such ISVDs, collectively TNF binders. Other aspects, embodiments, features, uses and advantages of the invention will be clear to the skilled person based on the disclosure herein. WO 2017/081320 Al MIDEDIMO1101010111010101011EIMM10010101101110VOIMIE — before the expiration of the time limit for amending the — with sequence listing part of description (Rule 5.2(a)) claims and amendments to be (Rule republished 48.2(h)) in the event of receipt of
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201562254375P | 2015-11-12 | 2015-11-12 | |
| PCT/EP2016/077595 WO2017081320A1 (en) | 2015-11-12 | 2016-11-14 | Improved tnf binders |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SG11201803975SA true SG11201803975SA (en) | 2018-06-28 |
Family
ID=57348648
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG11201803975SA SG11201803975SA (en) | 2015-11-12 | 2016-11-14 | Improved tnf binders |
Country Status (37)
| Country | Link |
|---|---|
| US (2) | US10544211B2 (en) |
| EP (2) | EP3191511B1 (en) |
| JP (2) | JP6962915B2 (en) |
| KR (2) | KR20240029115A (en) |
| CN (1) | CN108473563B (en) |
| AU (2) | AU2016352943B2 (en) |
| BR (1) | BR112018009714A8 (en) |
| CA (2) | CA3234178A1 (en) |
| CL (1) | CL2018001291A1 (en) |
| CO (1) | CO2018005915A2 (en) |
| CR (1) | CR20180311A (en) |
| CY (1) | CY1120303T1 (en) |
| DK (1) | DK3191511T3 (en) |
| DO (1) | DOP2018000122A (en) |
| EC (1) | ECSP18042569A (en) |
| ES (1) | ES2662418T3 (en) |
| GT (1) | GT201800095A (en) |
| HK (1) | HK1248716A1 (en) |
| HR (1) | HRP20171949T1 (en) |
| HU (1) | HUE035805T2 (en) |
| IL (2) | IL310373A (en) |
| LT (1) | LT3191511T (en) |
| MA (1) | MA41653A (en) |
| MD (1) | MD3191511T2 (en) |
| ME (1) | ME02954B (en) |
| MX (1) | MX385207B (en) |
| NO (1) | NO2768984T3 (en) |
| PE (1) | PE20181317A1 (en) |
| PH (1) | PH12018501025A1 (en) |
| PL (1) | PL3191511T3 (en) |
| PT (1) | PT3191511T (en) |
| RS (1) | RS56676B1 (en) |
| SG (1) | SG11201803975SA (en) |
| SI (1) | SI3191511T1 (en) |
| SM (1) | SMT201700590T1 (en) |
| TN (1) | TN2018000159A1 (en) |
| WO (1) | WO2017081320A1 (en) |
Families Citing this family (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US11644471B2 (en) | 2010-09-30 | 2023-05-09 | Ablynx N.V. | Techniques for predicting, detecting and reducing aspecific protein interference in assays involving immunoglobulin single variable domains |
| DK2723769T4 (en) | 2011-06-23 | 2022-09-05 | Ablynx Nv | TECHNIQUES TO PREDICT, DETECT, AND REDUCE UNSPECIFIC PROTEIN INTERFERENCE IN ASSAYS INVOLVING VARIABLE IMMUNE GLOBULIN SINGLE DOMAINS |
| IL295534B2 (en) | 2014-05-16 | 2025-03-01 | Ablynx Nv | Improved immunoglobulin variable domains |
| IL318433A (en) | 2014-05-16 | 2025-03-01 | Ablynx Nv | Improved immunoglobulin variable domains |
| NO2768984T3 (en) * | 2015-11-12 | 2018-06-09 | ||
| GB201522394D0 (en) | 2015-12-18 | 2016-02-03 | Ucb Biopharma Sprl | Antibodies |
| IL293554A (en) * | 2019-12-06 | 2022-08-01 | Ablynx Nv | Polypeptides comprising immunoglobulin single variable domains targeting tnfa and ox40l |
| IL293561A (en) * | 2019-12-06 | 2022-08-01 | Ablynx Nv | Polypeptides comprising immunoglobulin single variable domains targeting tnfa and il-23 |
| CN112300289B (en) * | 2019-12-30 | 2022-06-10 | 中国药科大学 | RGD4C fusion anti-TNF alpha nano antibody protein, preparation method and application thereof |
| KR20230123497A (en) * | 2020-12-18 | 2023-08-23 | 아블린쓰 엔.브이. | Polypeptide comprising an immunoglobulin single variable domain targeting IL-6 and TNF-α |
| WO2023093899A1 (en) * | 2021-11-29 | 2023-06-01 | 江苏恒瑞医药股份有限公司 | Modified protein or polypeptide |
| EP4611728A1 (en) * | 2022-11-04 | 2025-09-10 | St. Jude Children's Research Hospital, Inc. | Nlrp12 and nlrc5 modulators and methods for using the same to modulate diseases |
| US20240415974A1 (en) | 2022-12-23 | 2024-12-19 | Ablynx N.V. | Protein-based conjugation carriers |
| AR131869A1 (en) | 2023-02-17 | 2025-05-07 | Ablynx Nv | POLYPEPTIDES THAT BIND TO THE NEONATAL Fc RECEPTOR |
Family Cites Families (39)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE69330523D1 (en) | 1992-08-21 | 2001-09-06 | Vrije Universiteit Brussel Bru | IMMUNOGLOBULINE WITHOUT LIGHT CHAINS |
| EP0739981A1 (en) | 1995-04-25 | 1996-10-30 | Vrije Universiteit Brussel | Variable fragments of immunoglobulins - use for therapeutic or veterinary purposes |
| BR9813276A (en) | 1997-10-27 | 2000-08-22 | Unilever Nv | Multivalent antigen binding protein, nucleotide sequences, expression vector, host cell, process for preparing multivalent antigen binding protein, and use thereof |
| CN1316910A (en) | 1998-02-19 | 2001-10-10 | 埃克斯西特治疗公司 | Compositions and methods for modulating lymphocyte activation |
| US20060002935A1 (en) | 2002-06-28 | 2006-01-05 | Domantis Limited | Tumor Necrosis Factor Receptor 1 antagonists and methods of use therefor |
| US9321832B2 (en) | 2002-06-28 | 2016-04-26 | Domantis Limited | Ligand |
| US20060228355A1 (en) | 2003-11-07 | 2006-10-12 | Toon Laeremans | Camelidae single domain antibodies vhh directed against epidermal growth factor receptor and uses therefor |
| JP2006519763A (en) * | 2002-11-08 | 2006-08-31 | アブリンクス エン．ヴェー． | Method of administering therapeutic polypeptides and polypeptides therefor |
| EP2390270A1 (en) | 2003-01-10 | 2011-11-30 | Ablynx N.V. | Therapeutic polypeptides, homologues thereof, fragments thereof and for use in modulating platelet-mediated aggregation |
| DE602004017726D1 (en) | 2003-06-30 | 2008-12-24 | Domantis Ltd | Pegylated single-domain antibodies (dAb) |
| JP5113523B2 (en) | 2004-10-13 | 2013-01-09 | アブリンクス ナームローゼ フェンノートシャップ | Polypeptides comprising nanoantibodies against amyloid-β and nanoantibodies TM for the treatment of neurodegenerative diseases such as Alzheimer's disease |
| CA2588892A1 (en) | 2004-12-02 | 2006-06-08 | Dormantis Limited | Anti-il-1r1 single domain antibodies and therapeutic uses |
| EP2949668B1 (en) | 2005-05-18 | 2019-08-14 | Ablynx N.V. | Improved nanobodies tm against tumor necrosis factor-alpha |
| BRPI0609797B8 (en) | 2005-05-20 | 2021-05-25 | Ablynx Nv | improved nanobodies for the treatment of aggregation-mediated disorders |
| DE102005023617A1 (en) * | 2005-05-21 | 2006-11-23 | Aspre Ag | Method for mixing colors in a display |
| AU2006286563B2 (en) | 2005-08-30 | 2012-02-23 | Intrexon Actobiotics Nv | Anti-TNF alpha producing lactic acid bacteria for the treatment of chronic enterocolitis |
| EA200801166A1 (en) | 2005-12-01 | 2008-12-30 | Домантис Лимитед | FORMATS OF COMPETITIVE DOMAIN ANTIBODIES THAT ARE ASSOCIATED WITH INTERLEUKIN RECEPTOR FIRST TYPE 1 |
| JP2009519011A (en) | 2005-12-01 | 2009-05-14 | ドマンティス リミテッド | Non-competitive domain antibody format that binds to interleukin 1 receptor type 1 |
| FR2894741B1 (en) | 2005-12-08 | 2009-12-04 | Centre Nat Etd Spatiales | SATELLITE RECEPTION CHAIN |
| CA2640066A1 (en) | 2006-01-24 | 2007-08-02 | Roland Beckmann | Fusion proteins that contain natural junctions |
| AU2007285695B2 (en) | 2006-08-18 | 2012-05-24 | Ablynx N.V. | Amino acid sequences directed against IL-6R and polypeptides comprising the same for the treatment of diseases and disorders associated with IL-6-mediated signalling |
| US20080267949A1 (en) | 2006-12-05 | 2008-10-30 | Ablynx N.V. | Peptides capable of binding to serum proteins |
| WO2012130874A1 (en) | 2011-03-28 | 2012-10-04 | Ablynx Nv | Bispecific anti-cxcr7 immunoglobulin single variable domains |
| MX2009012650A (en) | 2007-05-24 | 2010-02-18 | Ablynx Nv | Amino acid sequences directed against rank-l and polypeptides comprising the same for the treatment of bone diseases and disorders. |
| AU2008328779B2 (en) | 2007-11-27 | 2014-06-05 | Ablynx N.V. | Amino acid sequences directed against HER2 and polypeptides comprising the same for the treatment of cancers and/or tumors |
| DE102008023620A1 (en) | 2008-05-15 | 2009-11-19 | Mettler-Toledo (Albstadt) Gmbh | Function unit with an invocable function and method for calling it |
| JP6034023B2 (en) | 2008-05-16 | 2016-11-30 | アブリンクス エン．ヴェー． | Amino acid sequences directed to CXCR4 and other GPCRs and compounds containing the same |
| EA022925B1 (en) * | 2009-02-19 | 2016-03-31 | Глаксо Груп Лимитед | Improved anti-tnfr1 polypeptides, antibody variable domains & antagonists |
| MX2011010681A (en) | 2009-04-10 | 2012-01-20 | Ablynx Nv | Improved amino acid sequences directed against il-6r and polypeptides comprising the same for the treatment of il-6r related diseases and disorders. |
| WO2010130832A2 (en) | 2009-05-15 | 2010-11-18 | Ablynx N.V. | Amino acid sequences directed against dickkopf-1 and polypeptides comprising the same for the treatment of diseases and disorders associated with bone loss and/or osteolytic lesions |
| SG177601A1 (en) | 2009-07-16 | 2012-02-28 | Glaxo Group Ltd | Improved anti-serum albumin binding single variable domains |
| US9120855B2 (en) | 2010-02-10 | 2015-09-01 | Novartis Ag | Biologic compounds directed against death receptor 5 |
| EP3466972A1 (en) | 2011-06-23 | 2019-04-10 | Ablynx NV | Serum albumin binding proteins |
| DK2723769T4 (en) * | 2011-06-23 | 2022-09-05 | Ablynx Nv | TECHNIQUES TO PREDICT, DETECT, AND REDUCE UNSPECIFIC PROTEIN INTERFERENCE IN ASSAYS INVOLVING VARIABLE IMMUNE GLOBULIN SINGLE DOMAINS |
| EA027160B1 (en) * | 2011-08-17 | 2017-06-30 | Глаксо Груп Лимитед | Modified proteins and peptides |
| WO2014111550A1 (en) | 2013-01-17 | 2014-07-24 | Glaxosmithkline Intellectual Property Development Limited | Modified anti-serum albumin binding proteins |
| IL295534B2 (en) | 2014-05-16 | 2025-03-01 | Ablynx Nv | Improved immunoglobulin variable domains |
| NO2768984T3 (en) * | 2015-11-12 | 2018-06-09 | ||
| CN108699151B (en) * | 2016-02-12 | 2022-08-12 | 埃博灵克斯股份有限公司 | Methods for preparing immunoglobulin single variable domains |
-
2012
- 2012-10-19 NO NO12841612A patent/NO2768984T3/no unknown
-
2016
- 2016-11-13 MA MA041653A patent/MA41653A/en unknown
- 2016-11-14 HR HRP20171949TT patent/HRP20171949T1/en unknown
- 2016-11-14 IL IL310373A patent/IL310373A/en unknown
- 2016-11-14 SG SG11201803975SA patent/SG11201803975SA/en unknown
- 2016-11-14 EP EP16798122.4A patent/EP3191511B1/en active Active
- 2016-11-14 PT PT167981224T patent/PT3191511T/en unknown
- 2016-11-14 SI SI201630013T patent/SI3191511T1/en unknown
- 2016-11-14 CN CN201680076588.6A patent/CN108473563B/en active Active
- 2016-11-14 MX MX2018005992A patent/MX385207B/en unknown
- 2016-11-14 ME MEP-2017-291A patent/ME02954B/en unknown
- 2016-11-14 AU AU2016352943A patent/AU2016352943B2/en active Active
- 2016-11-14 SM SM20170590T patent/SMT201700590T1/en unknown
- 2016-11-14 BR BR112018009714A patent/BR112018009714A8/en active Search and Examination
- 2016-11-14 DK DK16798122.4T patent/DK3191511T3/en active
- 2016-11-14 US US15/501,011 patent/US10544211B2/en active Active
- 2016-11-14 KR KR1020247005963A patent/KR20240029115A/en active Pending
- 2016-11-14 PL PL16798122T patent/PL3191511T3/en unknown
- 2016-11-14 CA CA3234178A patent/CA3234178A1/en active Pending
- 2016-11-14 LT LTEP16798122.4T patent/LT3191511T/en unknown
- 2016-11-14 CA CA3005085A patent/CA3005085C/en active Active
- 2016-11-14 ES ES16798122.4T patent/ES2662418T3/en active Active
- 2016-11-14 WO PCT/EP2016/077595 patent/WO2017081320A1/en not_active Ceased
- 2016-11-14 CR CR20180311A patent/CR20180311A/en unknown
- 2016-11-14 PE PE2018000766A patent/PE20181317A1/en unknown
- 2016-11-14 JP JP2018524836A patent/JP6962915B2/en active Active
- 2016-11-14 EP EP17184686.8A patent/EP3266798A3/en not_active Withdrawn
- 2016-11-14 KR KR1020187016731A patent/KR102641194B1/en active Active
- 2016-11-14 RS RS20171299A patent/RS56676B1/en unknown
- 2016-11-14 TN TNP/2018/000159A patent/TN2018000159A1/en unknown
- 2016-11-14 MD MDE20170066T patent/MD3191511T2/en unknown
- 2016-11-14 HU HUE16798122A patent/HUE035805T2/en unknown
- 2016-11-14 IL IL259269A patent/IL259269B2/en unknown
-
2017
- 2017-03-13 US US15/456,824 patent/US9745372B2/en active Active
- 2017-12-01 HK HK18108106.4A patent/HK1248716A1/en unknown
- 2017-12-19 CY CY20171101330T patent/CY1120303T1/en unknown
-
2018
- 2018-05-11 CL CL2018001291A patent/CL2018001291A1/en unknown
- 2018-05-11 GT GT201800095A patent/GT201800095A/en unknown
- 2018-05-11 DO DO2018000122A patent/DOP2018000122A/en unknown
- 2018-05-15 PH PH12018501025A patent/PH12018501025A1/en unknown
- 2018-06-05 EC ECIEPI201842569A patent/ECSP18042569A/en unknown
- 2018-06-08 CO CONC2018/0005915A patent/CO2018005915A2/en unknown
-
2021
- 2021-10-14 JP JP2021168871A patent/JP7357038B2/en active Active
-
2023
- 2023-01-10 AU AU2023200113A patent/AU2023200113A1/en active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| SG11201803975SA (en) | Improved tnf binders | |
| SG11201906341XA (en) | Improved serum albumin binders | |
| SG11201811431VA (en) | Multispecific antibodies against cd40 and cd137 | |
| SG11201808622SA (en) | Chimeric receptors to flt3 and methods of use thereof | |
| SG11201809700YA (en) | Gdf15 fusion proteins and uses thereof | |
| SG11201906961UA (en) | Polypeptide variants and uses thereof | |
| SG11201909957TA (en) | Engineered ligase variants | |
| SG11201910027YA (en) | Bispecific antibody against ox40 and ctla-4 | |
| SG11201810327XA (en) | Single domain serum albumin binding protein | |
| SG11201805870YA (en) | Bispecific t cell engaging antibody constructs | |
| SG11201900955VA (en) | T cell receptors and immune therapy using the same | |
| SG11201804510PA (en) | Biparatopic polypeptides antagonizing wnt signaling in tumor cells | |
| SG11201907451XA (en) | Substituted imidazo-quinolines as nlrp3 modulators | |
| SG11201907753TA (en) | Bispecific binding molecules that are capable of binding cd137 and tumor antigens, and uses thereof | |
| SG11201909868YA (en) | Compositions and methods of treating huntington's disease | |
| SG11201908719QA (en) | Biomarkers and car t cell therapies with enhanced efficacy | |
| SG11201909541WA (en) | Chimeric antibody/t-cell receptor constructs and uses thereof | |
| SG11201811432WA (en) | Rna for cancer therapy | |
| SG11201803934YA (en) | Compositions and methods for expression of multiple biologically active polypeptides from a single vector for treatment of cardiac conditions and other pathologies | |
| SG11201810933QA (en) | Anti-c5 antibodies and uses thereof | |
| SG11201808709VA (en) | T cell receptors | |
| SG11201811232XA (en) | Treatment of amd using aav2 variant with aflibercept | |
| SG11201900634VA (en) | Chimeric antigen receptor | |
| SG11201803958WA (en) | Nucleic acids encoding repetitive amino acid sequences rich in proline and alanine residues that have low repetitive nucleotide sequences | |
| SG11201808911SA (en) | Trispecific and/or trivalent binding proteins |